HealthDay on MSN4d
No Link Seen Between Preoperative GLP-1 RA Use and Postoperative Aspiration PneumoniaPreoperative glucagon-like peptide-1 receptor agonist use is not associated with short-term postoperative aspiration pneumonia.
Depression risk for patients receiving GLP-1 RA was slightly higher than those receiving SGLT-2i and lower than those receiving DPP-4i.
Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.
2d
HealthDay on MSNAAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize ComplicationsStopping GLP-1 RA treatment 14 days before total joint arthroplasty can minimize risks for complications, according to study findings.
For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.
HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use in patients with type 2 diabetes is linked to a reduced risk of developing certain hematologic cancers compared to insulin and metformin.
With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...
Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual ...
Although GLP-1 drugs have shown impressive results for weight loss, they are forcing employers to ask tough questions about whether to provide coverage. “It’s a complicated picture in terms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results